Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression

References

• Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT. Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 1991; 11: 5113–24
   PubMed Web of Science ®Google Scholar
• Schuuring E, Verhoeven E, Litvinov S, Michalides RJ. The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Mol Cell Biol 1993; 13: 2891–98
   PubMed Web of Science ®Google Scholar
• Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J 2004; 382(Pt 1)13–25
   PubMedGoogle Scholar
• Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997; 15: 1617–23
   PubMed Web of Science ®Google Scholar
• Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6: 3177–82
   PubMedGoogle Scholar
• Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992; 7: 355–61
   PubMed Web of Science ®Google Scholar
• Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, et al. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: Comparison with Epidermal Growth Factor Receptor status. Br J Cancer; (in press).
   Google Scholar
• Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873–8
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579–84
   PubMed Web of Science ®Google Scholar
• Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 2005; 65: 3273–80
   PubMed Web of Science ®Google Scholar
• Bozec A, Lassalle S, Gugenheim J, Fischel JL, Formento P, Hofman P, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006; 95: 722–8
   PubMed Web of Science ®Google Scholar
• Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (“Iressa”). Br J Cancer 2002; 86: 1518–23
   PubMed Web of Science ®Google Scholar
• Vouret-Craviari V, Boulter E, Grall D, Matthews C, Van Obberghen-Schilling E. ILK is required for the assembly of matrix-forming adhesions and capillary morphogenesis in endothelial cells. J Cell Sci 2004; 117(Pt 19)4559–69
   PubMedGoogle Scholar
• Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD. Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene 1996; 12: 31–5
   PubMedGoogle Scholar
• van Rossum AG, de Graaf JH, Schuuring-Scholtes E, Kluin PM, Fan YX, Zhan X, et al. Alternative splicing of the actin binding domain of human cortactin affects cell migration. J Biol Chem 2003; 278: 45672–9
   PubMed Web of Science ®Google Scholar
• Huang C, Liu J, Haudenschild CC, Zhan X. The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 1998; 273: 25770–6
   PubMed Web of Science ®Google Scholar
• Howell GM, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck 2005; 27: 710–7
   PubMedGoogle Scholar
• Lynch DK, Winata SC, Lyons RJ, Hughes WE, Lehrbach GM, Wasinger V, et al. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 2003; 278: 21805–13
   PubMed Web of Science ®Google Scholar
• Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: An emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349–57
   PubMed Web of Science ®Google Scholar
• Cheng Y, Leung S, Mangoura D. Transient suppression of cortactin ectopically induces large telencephalic neurons towards a GABAergic phenotype. J Cell Sci 2000; 113(Pt 18)3161–72
   PubMedGoogle Scholar
• Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, et al. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006; 66: 8017–25
   PubMed Web of Science ®Google Scholar
• Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007; 67: 9304–14
   PubMed Web of Science ®Google Scholar
• Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 2000; 89: 286–92
   PubMedGoogle Scholar